## Abstract ## Background The aim of this study was to evaluate the accuracy of positron emission tomography (PET) in assessing the patients treated with primary chemoradiotherapy for mucosal carcinoma of the head and neck. ## Methods A retrospective review of patients with biopsy‐proven cancer
Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer
✍ Scribed by Kathryn M. Greven; Daniel W. Williams III; W. Frederick McGuirt Sr.; Beth A. Harkness; Ralph B. D'Agostino Jr; John W. Keyes Jr; Nat E. Watson Jr
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 74 KB
- Volume
- 23
- Category
- Article
- ISSN
- 1043-3074
- DOI
- 10.1002/hed.1136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
A single institution study was undertaken to evaluate the role of positron emission tomography (PET) scans with fluorodeoxyglucose (FDG) prior to radiation and following radiation.
Methods
Forty‐five patients with head and neck cancers were evaluated with FDG‐PET scans as well as either CT or MRI prior to treatment with definitive radiation (RT). These same scans were obtained following completion of RT at 1 month (36 patients), 4 months (28 patients), 12 months (19 patients), and 24 months (15 patients). Standard uptake values (SUV) normalized for blood glucose and lean body mass were calculated on the initial and 1‐month post‐treatment PET scans.
Results
Fifteen patients are alive without evidence of disease at 24 to 52 months following RT. Initial SUVs were calculated on the primary tumor site and ranged from 2.5 to 28.5. These values did not have any correlation with local control when examined for the entire group, primary site, or T stage. One‐month post‐RT SUV ranged from 1.8 to 6.24. Of the 36 1‐month post‐RT PET scans, six were interpreted as positive for residual disease and were confirmed by biopsy. Four of the five scans, which were interpreted as equivocal, were positive on biopsy. Seven of the 25 scans, which were interpreted as negative for tumor, were positive on biopsy. Four‐month scans were more accurate for disease with disease noted in 0 of 18 negative scans, 6 of 7 positive scans, and 2 of 3 equivocal scans.
Conclusions
PET is useful for initial imaging of head and neck cancers. SUV does not appear to be useful for predicting outcome following treatment with RT. One‐month post‐RT scans were inaccurate for predicting the presence of cancer. Four‐month post‐RT scans were a better predictor for the presence of cancer. © 2001 John Wiley & Sons, Inc. Head Neck 23: 942–946, 2001.
📜 SIMILAR VOLUMES
## Background: [f-18]fluorodeoxyglucose (fdg)-positron emission tomography (pet) can measure the metabolic activity of tissues; fdg-pet may be able to predict response to chemotherapy by identifying changes in tumor metabolism. measurement of response to treatment may help improve survival in the m
## Abstract ## Objectives/Hypothesis: Planned neck dissection following chemoradiation (CR) has been advocated in patients with head and neck squamous cell cancer (HNSCC) with advanced nodal disease and a clinical complete response to CR because of the potential for residual occult nodal disease.
## Abstract ## Background Multiple oral complaints develop during radiation therapy for head and neck cancer, and quality of life is affected after treatment. The purpose of this investigation was to assess the quality of life, oral function, and oral symptoms in a cohort of patients during and af
## Abstract ## Background. The aim of this study was to determine the benefits of ^18^fluoro‐fluorodeoxyglucose positron emission tomography (^18^F‐FDG PET) in the detection of head and neck squamous cell carcinoma (HNSCC) recurrence in patients with negative clinical follow‐up. ## Methods. Whol